text:
Q: Entity Framework 5 RTM Code First enum support broken: enums in other namespaces This is about Entity Framework 5 RTM Code First.
When I map an entity having an existing enum I get this error:

No corresponding object layer type could be found for the conceptual
  type '[FULL ENUM TYPE NAME]'

Actually it looks for the whole enum in the same namespace of the DbContext.
Some other question (Using Enums with Code First & Entity Framework 5) had an answer that pointed to some blog post where there's a how-to on how to get this working but it talks about Database-First/Model-First approach.
How can I add an EDM enum type using Code-First approach?

A: I am afraid it isn't possible right now  - there is known bug in the EF5 http://entityframework.codeplex.com/workitem/532, that is causing the mentioned error.
I was struggling with the similar problem and didn't find any elegant solution. I ended up with int column instead of enum column.
Edit (problematic model):
Core assembly:
public enum UserStatus { Approved, Disabled }

public interface IUser {
    public int ID { get; }
    public string Username { get; set;}
    public UserStatus Status { get; set;}
}

Users assembly:
public class User : IUser {
    public int ID { get; protected set; }
    public string Username { get; set; }
    public UserStatus Status { get; set; }
}

redpajama_set_name: RedPajamaStackExchange


text:
Konrad der Ältere († 27. Februar 906 bei Fritzlar) aus dem Haus der Konradiner war ein Sohn des Grafen Udo im Lahngau (um 830–879) und der Vater des späteren deutschen Königs Konrad I. Konrad wird als nepos (Neffe, Enkel, Nachkomme) des Königs Arnulf bezeichnet, der mit Oda, einer Verwandten Konrads, verheiratet war.

Leben
Konrad war 886 Graf im Oberlahngau, Graf im Wormsgau, ab 897 Graf im Hessengau, 903 Graf im Gotzfeldgau und 905 Graf in der Wetterau. Nachdem Arnulf den fränkischen Babenberger Markgrafen Poppo von Thüringen gestürzt hatte, wurde Konrad 892 als Verwandter der Königin mit der Nachfolge Poppos betraut. Gleichzeitig wurde Konrads Bruder Rudolf zum Bischof von Würzburg ernannt, womit die Konradiner einen beherrschenden Einfluss nicht nur in Hessen, sondern nun auch in Thüringen und Mainfranken gewannen.

Als Arnulf Ende 899 starb und kurz darauf sein siebenjähriger Sohn Ludwig das Kind, der Sohn Odas, zum König gewählt wurde, gewannen Konrad und seine Familie erheblichen Einfluss auf die Reichspolitik. Konrad konnte sich allerdings in Thüringen gegen die mächtiger werdenden Liudolfinger nicht behaupten, und diese Markgrafschaft ging daher bereits vor 903 wieder verloren. Dafür wuchs der Familie mit dem Titel eines dux regni Lothringens für Konrads Bruder Gebhard weitere Macht zu. Konrad stand ab 902 in einer blutigen Fehde mit den Babenbergern, in der er 906 bei Fritzlar den Tod fand. Dies führte sehr schnell die Gefangenschaft und Hinrichtung des letzten Babenbergers, Adalbert, herbei. Konrad wurde in der Martinskirche in Weilburg beerdigt.

Der Tod Konrads des Älteren und das Ende der Babenberger machte den Weg frei für Konrads Sohn, Konrad den Jüngeren, der dann mit dem Titel dux (Herzog) in Main- und Rheinfranken herrschte und 911 zum König des Ostfränkischen Reichs gewählt wurde.

Familie
Konrad war ab etwa 880 verheiratet mit Glismut (* um 866; † 26. April 924), Tochter von Kaiser Arnulf von Kärnten. Mit ihr hatte er vier Kinder:
 Konrad der Jüngere († 918), 910 Herzog von Franken, 911 ostfränkischer König
 Eberhard († 939), 918 Herzog von Franken
 Otto bzw. Udo od. Odo († nach 918), 904 Graf im Ruhrgau, 912 Graf an der mittleren Lahn
 Tochter ∞ Burkhard

Konrads Vater war Udo im Lahngau, seine Brüder waren:
 Gebhard (888 bezeugt; † (22.) Juni 910 bei Augsburg), 897 und 906 Graf im oberen Rheingau, 909 Graf in der Wetterau, 903 Herzog in Lothringen (dux regni)
 Rudolf († 3. August 908 in Thüringen), 892–908 Bischof von Würzburg

Herzog (Franken)
Gaugraf
Gaugraf (Hessen)
Familienmitglied der Konradiner
Person (Thüringer Geschichte)
Geboren im 9. Jahrhundert
Gestorben 906
Mann

redpajama_set_name: RedPajamaWikipedia


Optimising and updating the tried and trusted Z21® app gives you the benefit of a whole range of new, highly desirable functions and options that you can use to experience your digital model railway in even greater exciting detail.
The app is available for iOS devices in the App Store and for Android devices in the Google Play Store for complimentary download.
Easy touch operation to switch turnouts, signals, etc.
The Z21® app also allows you to carry out CV programming to further optimise the driving response and thus the driving pleasures on your system.
The import and export function means that model railway systems can be exchanged easily between devices and with friends.
A particular plus point in favour of changing to a digital model railway is the option to control your locomotives yourself as the actual driver.
Be wowed by the photorealistic driver cabs with original switches and control elements. Every control knob or lever can be operated directly and has exactly the same effect on your locomotive as it would on the rails in real life.
The Z21® app currently includes 8 individual driver cabs.


text:
Walter Klimecki
Adjunct Associate Professor, Nursing
Assistant Professor, Medicine - (Research Scholar Track)
Associate Professor, BIO5 Institute
Associate Professor, Genetics - GIDP
Associate Professor, Pharmacology and Toxicology
Associate Professor, Public Health
Associate Professor, Veterinary Medicine
Vet Med Administration
wtk@email.arizona.edu
Walter Klimecki's research program involves the balance between the particular DNA sequence "versions" of genes that we inherit from our ancestors, and the particular environmental exposures that we experience throughout our lives. The Klimecki lab studies diseases resulting from human exposure to arsenic, contributing to a better understanding of the inherited genetic differences between people that result in altered chemical processing of arsenic after it enters the body.
Walter T. Klimecki, DVM, PhD, is an Associate Professor in the Department of Pharmacology and Toxicology in the College of Pharmacy at the University of Arizona. Dr. Klimecki holds joint appointments in the College of Medicine, the College of Public Health, and the Arizona Respiratory Center. He is a Full Member of the Southwest Environmental Health Sciences Center (SWEHSC) where, together with BIO5 director Martinez and BIO5 Statistics Consulting Service director Billheimer, he leads the Integrative Health Sciences (IHS) Center at SWEHSC. The IHS is a translational research support core at SWEHSC, focused on lowering the "activation energy" for translational research.Dr. Klimecki's research focuses on the toxicology of metals in the environment, an issue particularly relevant in our mining-intensive state. His research work has encompassed a wide range of experimental approaches, from epidemiological studies of arsenic-exposed human populations, to laboratory models including cell culture and rodents. Using cutting edge genetics tools, Dr. Klimecki's group recently published the first report of an association between human ancestry and response to environmental toxicants. In this provocative work, his group found that individuals whose genomes were comprised of DNA with its origins in the indigenous American populations processed ingested arsenic in a less harmful manner than did individuals whose genomes had their origins in Europe. Using laboratory models his group made ground-breaking discoveries of the impact of arsenic exposure on a process known as autophagy, in which cells digest parts of their own machinery in a sort of "cash for clunkers" arrangement. The ability of arsenic to perturb this process is only now being appreciated by the toxicology community, thanks to the work of the Klimecki Lab. Dr. Klimecki was recently elected as a Vice President-elect to the Metals Specialty Section of the Society of Toxicology, the preeminent scientific toxicology organization in the world. Dr. Klimecki's research is highly collaborative: his grants and publications have included many BIO5 members, including BIO5 director Fernando Martinez, and BIO5 members Donata Vercelli, Dean Billheimer, and Marilyn Halonen.
Association of children's urinary CC16 levels with arsenic concentrations in multiple environmental media
Beamer, P., Loh, M. M., Klimecki, W., Ornelas Van Horne, Y., Sugeng, A. J., Lothrop, N. Z., Billheimer, D. D., Guerra, S., Lantz, R. C., Canales, R. A., & Martinez, F. (2016). Association of children's urinary CC16 levels with arsenic concentrations in multiple environmental media. International Journal of Environmental Research and Public Health .
BIO5 Collaborators
Paloma Beamer, Dean Billheimer, Stefano Guerra, Walter Klimecki, Clark Lantz, Fernando Martinez
Response to García-Nieto et al. Comments on Beamer et al. Association of Children's Urinary CC16 Levels with Arsenic Concentrations in Multiple Environmental Media. Int. J. Environ. Res. Public Health 2016, 13, 521
Beamer, P. I., Klimecki, W. T., Loh, M., Van Horne, Y. O., Sugeng, A. J., Lothrop, N., Billheimer, D., Guerra, S., Lantz, R. C., Canales, R. A., & Martinez, F. D. (2016). Response to García-Nieto et al. Comments on Beamer et al. Association of Children's Urinary CC16 Levels with Arsenic Concentrations in Multiple Environmental Media. Int. J. Environ. Res. Public Health 2016, 13, 521. International journal of environmental research and public health , 13(10).
We would like to thank the editors for providing us with the opportunity to respond to the points raised by Dr. García Nieto.[...].
Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease
Lake, A. D., Novak, P., Fisher, C. D., Jackson, J. P., Hardwick, R. N., Billheimer, D. D., Klimecki, W. T., & Cherrington, N. J. (2011). Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition , 39(10), 1954-1960.
Dean Billheimer, Nathan J Cherrington, Walter Klimecki
PMID: 21737566;PMCID: PMC3186211;Abstract:
Nonalcoholic fatty liver disease (NAFLD) is characterized by a series of pathological changes that range from simple fatty liver to nonalcoholic steatohepatitis (NASH). The objective of this study is to describe changes in global gene expression associated with the progression of human NAFLD. This study is focused on the expression levels of genes responsible for the absorption, distribution, metabolism, and elimination (ADME) of drugs. Differential gene expression between three clinically defined pathological groups - normal, steatosis, and NASH - was analyzed. Genome-wide mRNA levels in samples of human liver tissue were assayed with Affymetrix GeneChip Human 1.0ST arrays. A total of 11,633 genes exhibited altered expression out of 33,252 genes at a 5% false discovery rate. Most gene expression changes occurred in the progression from steatosis to NASH. Principal component analysis revealed that hepatic disease status was the major determinant of differential ADME gene expression rather than age or sex of sample donors. Among the 515 drug transporters and 258 drug-metabolizing enzymes (DMEs) examined, uptake transporters but not efflux transporters or DMEs were significantly over-represented in the number of genes down-regulated. These results suggest that uptake transporter genes are coordinately targeted for down-regulation at the global level during the pathological development of NASH and that these patients may have decreased drug uptake capacity. This coordinated regulation of uptake transporter genes is indicative of a hepatoprotective mechanism acting to prevent accumulation of toxic intermediates in disease- compromised hepatocytes. Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics.
Genetic Variant in ACVR2B Is Associated with Lean Mass
Klimentidis, Y. C., Bea, J. W., Thompson, P., Klimecki, W. T., Hu, C., Wu, G., Nicholas, S., Ryckman, K. K., & Chen, Z. (2016). Genetic Variant in ACVR2B Is Associated with Lean Mass. Medicine and science in sports and exercise .
Zhao Chen, Chengcheng Hu, Walter Klimecki, Yann C Klimentidis
Low lean mass (LM) is a risk factor for chronic disease, a major cause of disability and diminished quality of life, and is a heritable trait. However, relatively few specific genetic factors have been identified as potentially influencing this trait.
Association between body mass index and arsenic methylation efficiency in adult women from southwest U.S. and northwest Mexico
Gomez-Rubio, P., Roberge, J., Arendell, L., Harris, R., O'Rourke, M., Chen, Z., Cantu-Soto, E., Meza-Montenegro, M., Billheimer, D., Lu, Z., & Klimecki, W. (2011). Association between body mass index and arsenic methylation efficiency in adult women from southwest U.S. and northwest Mexico. Toxicology Applied Pharmacology , 252(2), 176-182.
Dean Billheimer, Walter Klimecki
College of Pharmacy Study Looks At Efficacy of Student PGET As An Educational Tool

redpajama_set_name: RedPajamaCommonCrawl


text:
Bonds News
Yankees want more NYC bonds for stadium: Brodsky
By Joan Gralla
NEW YORK (Reuters) - The New York Yankees baseball team wants a city agency to sell $350 million of bonds for its new stadium or else it will not be able to complete the project, state Assemblyman Richard Brodsky said on Tuesday.
The foul pole in Yankee Stadium is framed by a rampway as it waits for opening day where the New York Yankees and the Toronto Blue Jays will play in New York March 30, 2008. REUTERS/Ray Stubblebine
The Internal Revenue Service, however, would have to approve the new bond sale. The federal tax agency cracked down on financing these types of projects with tax-exempt debt after the Yankees got a waiver for the first sale of debt for their new stadium in the Bronx, the Westchester Democrat said.
"Right now, they (the Yankees) are saying they don't think they can complete the stadium unless the Internal Revenue Service ruling is reversed and they apparently have been joined in this effort to reverse the ruling by the Nets and the Mets," Brodsky told Reuters by phone.
However, Yankees President Randy Levine said: "This will not affect the completion of the stadium."
Levine and the city's debt-selling agency confirmed they wanted a waiver from the IRS. "We are working under the strong leadership of the city and state to try to seek relief from the regulations," Levine said.
The Yankees, one of the most profitable U.S. sports enterprises, once threatened to move out of the Bronx.
Though the team that has won 26 World Series titles decided to stay put, civic advocates say they and their cross-town rivals, the Mets, got overly rich taxpayer subsidies.
The new Yankee stadium is expected to open in 2009, replacing the 1923 stadium made famous by Babe Ruth.
In addition to other benefits, the city's Industrial Development Authority in 2006 sold $941 million of tax-exempt bonds for the Yankees and $548 million of debt for the Mets, whose Shea Stadium in Queens dates back to 1964.
The Mets, a team that has won two World Series titles, plan to open a new home in Queens next year.
The National Basketball Association's Nets now play in New Jersey but plan to build a new arena in Brooklyn that will anchor a billion-dollar office and housing development, which now faces a cooling real estate market.
Tax-exempt debt is crucial for the new basketball arena's financing. The Nets, which won two championships when they were in the American Basketball Association, plan to open the Brooklyn arena in time for the 2010-2011 season.
Janel Patterson, an Industrial Development Authority spokeswoman, confirmed the city would consider selling more debt for the Yankees and said the IRS ruling blocks other projects.
"The City is working with the State in Washington to seek relief from the applicable IRS regulation, as this regulation has taken away a tool that would be useful for a number of important, New York economic development projects, not just Yankee Stadium," she said in a statement.
A spokesman for the Nets had no immediate comment. A spokesman for the Mets was not immediately available.
Brodsky demanded reforms and more accountability, saying: "The explosion of public debt issued by obscure semi-public and private institutions is reaching unmanageable proportions."
Brodsky also questioned if a city corporation, the Capital Resource Corporation that now plans to sell debt formerly sold by another agency, had met disclosure requirements.
He added: "These deals are usually negotiated secretly, with little accountability or public oversight, and directly or indirectly leave taxpayers on the hook.
Editing by Braden Reddall


Tory Burch puts her signature vintage pattern on this Jemini skirt. The chain print recalls the silk scarves of the 70s, a precious memory of generations past. The cut is just as classic, with an A-line shape and a box pleat in the front for a very modern finish. This skirt can be worn with sneakers and a T-shirt or with mules and a tank top.


text:
Mike Malak
Donald Trump, Moron, Dotard, Goldwater rule: A page is turned
Some say one man's madness is another man's strategy. Vanity Fair is calling it "Moron-gate," except the dotard in the cupboard isn't Donald Trump, it's Rex Tillerson who takes the dunce cap for his flip, petty, slap at the President, by calling Trump a "moron," for one thing, or another. If "Moron-in-Chief" becomes as quintessentially defining of President Trump as "Crooked Hillary" is of his nemesis, it's on Tillerson.
Published in Donald Trump News Today
Goldwater rule
Dotard
morongate
Donald Trump, on a "roll" with Puerto Rico post-Hurricane gaffes, slights, neglects
It was "a lovely visit, a first, too," the President said. No doubt, Donald Trump was the first U.S. President to throw rolls of paper towels into a tepid crowd of puzzled people the way a low-rent concert promoter tosses out second act t-shirts. What made it even stranger was that Trump hefted them to victims of drenching hurricanes. Golf towels would've been a better choice, especially since Houston got very nice, hot-boxed lunches. Whoever stage-managed this inept trip needs to quit because they ruined another chance for Trump to look good again.
Puerto Rico, Trump, Golf Trophy: Lazy gets the Birdie
The President dedicated a golf trophy on Sunday to the citizens of Texas, Florida, and the lazy, broke, infrastructure-challenged Puerto Ricans who want everyone to do everything for them. Devastated, homeless, foodless, waterless, powerless, and despairing, Donald Trump blamed them for their own woes in the same breath he used to praise himself for helping these American citizens. Would that this were true.
Monday, 25 September 2017 12:24
Trump's latest non-presidential insult rant yields NFL knee-jerk reactions
President Donald Trump's irresistible impulse to take on everyone, and anyone, over anything, consequential or not, is a detriment to Republican values and leads to the inescapable question of whether Trumpism needs Trump, any longer, to advance its mission.
How much does the Trump bridge to Putin link to Felix Sater?
Describing the Yalta Conference, FDR once said, "It is permitted in time of great danger to walk with the devil until you have crossed the bridge." Held from February 4-11, 1945, the conference was convened by Roosevelt, Churchill, and Stalin to wrap up WWII in Europe. Almost from the start, Stalin ignored the agreement as he expanded Soviet influence over Eastern and Western Europe, precipitating a chillier kind of war.
Felix Sater
Paul Manafort
Thursday, 14 September 2017 14:29
Donald Trump, The Deal-Making Democrat
"Progress Again!" Donald Trump can have the success he craves, and breach the mega-chasm of civil division afflicting the country if he becomes a Democrat. It would mean campaigning for Democratic Senate and House candidates next Fall, but he could do it. Chuck and Nancy would help, and the public would reward the new show with high ratings.
What's the deal with Team Trump, Huckabee Sanders, Russia and Comey?
Yabba, dabba do! It's back to James Comey is a liar according to Sarah Huckabee Sanders, White House Press Secretary. "He lied," she averred Monday, and claimed there's new information that supports Comey's firing as FBI Director. Brand new stuff! Can't wait! Comey's alleged dishonesty when he famously appeared before Congress to discuss his firing, Sanders said, was a matter for DOJ to investigate. She's just a tad late and a dollar short.
Hurricane Robert Mueller wrecking havoc upon mainland Donald Trump
Hurricanes are wreaking havoc. The West is ablaze. Iceland is melting. Nature is in an uproar and Rick Perry still doesn't believe in climate change. And, then, there's Kim Jong Un threatening WWIII. In the meantime, in Washington, Donald Trump is making financial deals with Democrats as President Gen. John Kelly runs the White House like a Marine battalion. Through it all, Special Counsel Robert Mueller plods along, trudging through the muddy night like Diogenes seeking just one honest man.
Thursday, 31 August 2017 20:34
Mueller-Schneiderman team stronger than Trump-Putin on Russia probe
Special Counsel Robert Mueller is no fool. He's aware of the rumors that President Donald Trump may try to fire him, or pardon those alleged to have violated federal law during, or before, the 2016 election. Should a pardon happen, in one scenario, Mueller's work product is likely to be trucked to the Department of Justice, sealed, and given a disclosure date of fifty years from now. To insure this doesn't happen, Mueller is said to be sharing his evidence with New York Attorney General Eric Schneiderman.
Schneiderman
Monday, 28 August 2017 14:40
Here's how Trump could pay for Mexican wall
President Trump could build a wall and might make Mexico pay for it, indirectly, if he constructed it out of solar panels and wind turbines. Equip the turbines with infrared motion cameras and long range omnidirectional microphones. Where the border is sensitive, capacity for human observation decks can be built into the turbines. Drones, also, could be turbine based and the wall could be fitted with satellite run gyros to lift, and turn, panels to enable them to track the path of the sun for utmost efficiency.
Bayoubuzz, Cloud
confederate monuments Coronavirus Covid19 Derrick Edwards Desiree Charbonnet Donald Trump Eddie Rispone fiscal cliff impeachment Joe Biden John Bel Edwards John Couvillon John Kennedy John Schroder LaToya Cantrell Louisiana Louisiana budget Louisiana elections Louisiana governor Louisiana governor's race Louisiana legislature Mitch Landrieu Nancy Pelosi New Orleans New Orleans Mayor New Orleans Mayor's race New Orleans Saints Ralph Abraham Robert Mueller Trump


SpectraQuest's Rotor Dynamics Test Rig System has been specifically designed to simulate different rotor dynamics phenomena for experimental and educational purposes. With the innovative design of two rotor assemblies connected in series, the customer has more choices in selecting different rotor parameters. Most of the rotor dynamic topics can be simulated and studied with this system.
The test rig was fabricated to give the customer much more choices in selecting rotor parameters in rotor dynamics testing through a two serial rotor systems design. A comprehensive rotor dynamic modeling was performed to determine critical speed and stability parameters.
The system consists of two rotors with different rotor dynamic characteristics. Rotor A is stiff rotor with the first critical speed at least 20% below the maximum operating speed. Rotor B is soft rotor exhibiting the second critical speed at least 20% below the maximum operating speed. The system can be customized to meet any critical speed requirements.
An outstanding feature is the rotor support stiffnesses can be varied in both the horizontal and vertical directions to obtain different aspect ratios. This is designed to study different orbits in rotor dynamics. The user can also measure horizontal and vertical dynamic forces at the bearing housings.
The test rig is fully modular so that both rotors, gear box, and motors can be relocated to obtain variety of machine configurations. It can be fitted with either rolling element or fluid film bearings. For fluid film bearing the user can install sleeve or tilting pad bearings. This is a versatile to perform many different rotor dynamics experiments.
Convenient and safe instrument mounting and wiring.


Creating lifelong possibilities for young women in the community.
Here's an opportunity for you to share your wisdom, experience, talent and resources in a way that will reward your heart and enrich the lives of many young women.
Whether you spend an hour a month, tap into your network to set up a Career Tour, or just drop by to say hello and show your support – rest assured that your effort and your participation will be greatly appreciated.
One thing you can do that will take just a moment is to give us suggestions for how our girls can perform community service hours, preferably in their area (because of transportation).
If you are interested in outreach opportunities, please contact Susan Prins, VP or Mentorship.


The company had stated that the investigative report prepared by two external agencies had found no evidence to prove these allegations.
Infosys founder NR Narayana Murthy has asked the company's Board to make public, the contents of the report that probed into alleged irregularities involving certain key acquisitions. Infosys, however, has stated that the company does not want to make the report public, in a response to FE's query on the matter. The company had stated that the investigative report carried out by two external agencies had found no evidence to prove these allegations. Earlier, anonymous complaints had alleged that there were irregularities in connection with company's acquisitions of Panaya and Skava in 2015. It had also alleged that the mergers and acquisitions team had acted without securing proper approvals. It also stated that CEO Vishal Sikka had received inappropriate compensation and incurred excessive expenses relating to travel, security and the Palo Alto office.
According to sources, Murthy has sought further clarity on the financial transactions in the acquisitions done by Infosys especially with regard to Panaya and also a closer scrutiny on the executives involved in these transactions. Murthy had in February this year publicly raised certain corporate governance issues at Infosys which also included severance payments made to former CFO Rajiv Bansal and former general consul David Kennedy. He felt that it was the board's responsibility to ensure the corporate governance standards.
Infosys then conducted an investigation with the help of external agencies which included Gibson Dunn & Crutcher, Control Risks and Khaitan & Company. As disclosed in June, the summary of the report had said, "We found no evidence whatsoever to support any of the new allegations in the complaints regarding wrongdoing by the company or its directors and employees, and those allegations were rebutted by substantial and credible evidence." According to Infosys, the investigation by the external agencies involved interviews of over 50 witnesses in India, the United States, and elsewhere.
It also involved the review of company policies, Board minutes, public filings and internal documents, the collection, search and review of many thousands of internal emails and attachments, the use of forensic accounting experts to analyze technical and financial information, the review of public filings and media accounts in multiple countries. The fresh salvo by Murthy is likely further strain the relationship between the Board and the founders. The board has already formed a committee to act as a bridge between the two group even as chairman R Seshasayee has consistently stated that they have harmonious relationship with the founders.
Seshasayee during the recently conducted AGM had said, "The Board has continuously engaged with all major investors in particular with the founders, and will continue to do so." The chairman also said that he will complete his term which ends in May next year. The Infosys board had recently elevated Ravi Venkatesan as the co-chairman.


on Saturday, April 22, 2017 and Sunday, April 23, 2017.
at the Jasenovac Monument at the Holocaust Memorial Park, Brooklyn, from 3 to 4 PM.
and the conference runs from 4:30 to 7:00.
For more information please call 917-254-5164.
and rededicate ourselves to the struggle for truth and justice for the victims of Ustashe and Nazi genocide.


text:
Workit Health
Nurse Practitioner, Physician Assistant
As a full-time or part-time Nurse Practitioner or Physician Assistant at Workit Health, you will be responsible for collaborating with a physician to provide care to patients. Workit Health Clinic Nurse Practitioners and Physician Assistants are providers that see patients both in person at Workit Clinics and via tele-health platforms. Currently, all of our positions are remote until further notice.
Facilitating live and interactive clinical assessments, treatments, and medication management in-person and via telehealth technologies
Making appropriate assessments, treatment plans, and referrals for patient problems
Prescribing and monitoring opiate replacement (Suboxone) therapy
Treating and managing members that are interested in moderating or abstaining from alcohol with medications such as Naltrexone and Acamprosate
Treating and managing the members other co-occurring illnesses including, but not limited to anxiety, depression, insomnia, and hepatitis C.
Providing patient education and referrals, specific to patients' assessed needs and abilities
Utilizing good communication skills, verbal and written
Exercising good physical diagnosis skills
Maintaining accurate records on patients treated
Participating in case reviews, consultations, and utilization review
Active State Nurse Practitioner or Physician Assistant license
DATA 2000 Waiver at 100
Ability and willingness to be licensed in multiple states
State controlled substance license or in the process of obtaining it
DEA Certificate or in the process of obtaining it
Holds a collaborative agreement or attestation with physician in accordance with the regulations of the state practicing in
Meets credentialing requirements where assigned, as well as the ability to be credentialed with Medicare and Medicaid and other payers as necessary
DATA 2000 Waiver
All NPs and PAs need to possess the DATA 2000 waiver and DEAx.
The Drug Addiction Treatment Act (DATA 2000) allows qualified physicians, nurse practitioners, and physician assistants to obtain a waiver to treat opioid addiction with otherwise restricted medication in any clinical setting where they are licensed to practice. Once a practitioner receives the waiver, they are authorized to prescribe buprenorphine for opioid addiction treatment in any setting for which they are otherwise credentialed to practice. NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients.
In order to qualify for the DATA 2000 waiver, you must be:
Licensed under state law
Registered with the DEA to prescribe controlled substances
Capable of referring patients to counseling and other services
Qualified by training and/or certification
In order to become qualified, CARA requires that nurse practitioners and physician assistants complete 24 hours of training to be eligible for a prescribing waiver. Some of these trainings have a cost associated with them, and all of the trainings are done online.
Click here for more information about obtaining the DATA 2000 waiver.
Why Join Workit?
Workit Health is a team of thinkers and doers disrupting the status quo of care through telemedicine.
We are a rapidly growing telemedicine B-corporation that puts members first in ensuring they receive the best possible care in addiction and beyond.
We are a group of solution architects passionate about creating more accessible opportunities for people to help people make life-long change.
Workit Health is an on-demand, evidence-based addiction treatment provider changing the way care is delivered. By leveraging telemedicine and a medication-first approach, we are improving clinical outcomes and enabling more individuals to enter long-term recovery.
We're excited to expand the team as our impact continues to grow. The dedication our team members bring to the table reflects our mission-driven culture of improving addiction through patient-centered design. We are looking for driven and compassionate individuals with a desire to transform an entire health ecosystem ripe for disruption.
Workit Health is proud to be an Equal Employment Opportunity and Affirmative Action employer. We do not discriminate based upon race, religion, color, national origin, gender (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, status as a protected veteran, status as an individual with a disability, or other applicable legally protected characteristics.
About Workit Health
Workit Health is the industry-leading provider of clinically proven telemedicine treatment for substance use disorder, offering online therapy, medication-assisted treatment, psychiatric support, and primary care via the Workit Health mobile app. From the privacy of their own homes, Workit members meet with clinicians, counselors, and coaches and work towards self-determined recovery goals. The easy-to-use program allows members to join online recovery groups, virtually drug test, and complete an interactive recovery curriculum.
With simple online scheduling, virtual visits, and medication e-prescribed to a local pharmacy, Workit Health makes it simple for people to receive the gold standard of substance use disorder treatment at the moment they're ready for help. Not everyone struggles with standalone substance use disorder, so Workit offers support for common co-occurring mental and physical conditions, including anxiety, depression, insomnia, hepatitis C, and PrEP for HIV.
Workit Health is a B-corporation dedicated to making a positive social impact, is accredited by the Joint Commission, and has partnered with the National Science Foundation and National Institute on Drug Abuse. The company is headquartered in Michigan, with over 250 employees nationwide and clinic locations in ten states. Learn more at workithealth.com.


text:
Bulbostylis guineensis är en halvgräsart som beskrevs av Henri Chermezon och Pierre Henri Hippolyte Bodard. Bulbostylis guineensis ingår i släktet Bulbostylis och familjen halvgräs.

Artens utbredningsområde är Guinea. Inga underarter finns listade i Catalogue of Life.

Källor

Halvgräs
guineensis


When your garage door opener needs replacement, go with the best. A-Authentic Garage Doors and a LiftMaster garage door opener. You can't do better.
LiftMaster offers a selection of keyless entry systems and control panels will provide you with added security and convenience features. With these systems you do not need to use a key or remote to enter your garage. 877MAX Wireless Keyless Entry SystemUse a private 4-digit code programmed directly into the unit. Security+2.0™ and Security+® rolling code technology assures a new code is sent every time the keypad is used. Works with all LiftMaster garage door openers manufactured since January 1993.
| 895MAX 3-Button Premium Remote ControlMyQ enabled accessory to turn on the house lights from your car.
Remote controls that can open up to four garage doors from a large distance. 374LM 4-Button Remote Control4 buttons to open or close garage doors or gates Can turn on interior lights and small appliances in your home Features Security+® rolling code technology that sends a brand new code every time it is used.
975LM Laser Parking AccessoryLaser positioning beam automatically appears on a pre-determined spot your dash board for you know exactly where to stop.


a penchant towards ethical means makes no difference. 2014 What is emotional intelligence and how can it be developed in people? Knowing the strict laws pertaining to road accidents you are aware that your honest account of the incident would lead to the prosecution of the manager and as a consequence the deal is likely to be jeopardised, which is of immense importance to your company. For example, a medical case study might study how a single patient is affected by an injury. Disclosure of the information is likely to lead to disciplinary action with possibility of punishment against him as well as some of his colleagues. 2013 Public Org- Dilemma GS4 Syllabus Topic: problems, dilemmas in Public Administration and public service. Just ignore thinking about it because it is their personal matter. Fourth general studies paper is ethics, integrity, aptitude. In fact, he's not even completely sure what it is!
The new plant may result in increased cost of living, aliens migrating to the region, disturbing the social and economic order. However, the payment is often tardy. The Government has also announced tax holiday for five years for the companies that invest in underdeveloped areas. Case-Study: Wife-beater Boss: To do something or not? 12 Send copies of the study to the client you collaborated with as well, along with a certificate thanking them for their involvement. 2016s GSM4 paper (12Q x 150 words) (4Q x 250 words) (2Q x 300 words) Total length: 3400 words 50 words longer paper. There is a primary school run by the government in your area.


Kowalskie syna – The kowal z Wioska Odmęty doesn't live alone, nor is he the only kupiec. He and his żony have a syn who also trades in weapons, armor and related products as part of the family business. The boy doesn't seem really into doing it, but he has to obey his father's wishes, apparently "or else!". The lad can be found next to the his father's shop, looking forlorn. Like most teenagers, he seems to get up relatively late as well.


All content, data and material contained on this Site are protected by one or more copyrights, trademarks, patents, trade secrets and/or other proprietary rights owned or licensed by us and which are protected under the laws of the State of Minnesota, the United States, foreign jurisdictions, and/or international treaties.
No portion or element of this Site or any of its content may be copied or retransmitted via any means. This Site, its content and all related rights shall remain our exclusive property or the property of the licensors of such content unless otherwise expressly agreed in writing. Without our prior written authorization, you may not reproduce, distribute, modify, display, perform, prepare derivative works based on, adapt, repost, or otherwise use the content or services of this Site. Use of this Site does not constitute a grant of any license or other right to use or exploit any of these proprietary rights.
Information on this Site may contain typographical errors, inaccuracies, or omissions in relation to product and services descriptions, information, and other matters. We reserve the right, but have no obligation, to correct any errors, inaccuracies, or omissions and to discontinue, change or update information or products or services at any time without prior notice.
THIS SITE AND ALL CONTENT, PRODUCTS, materials, and services available through THE SITE ARE PROVIDED ON AN "AS IS, WITH ALL DEFECTS" AND "AS AVAILABLE" BASIS WITHOUT WARRANTIES OF ANY KIND, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE. WE DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, SATISFACTORY QUALITY, ACCURACY OF INFORMATIONAL CONTENT, AND ANY WARRANTIES ARISING OUT OF ANY COURSE OF DEALING OR USAGE OF TRADE. We MAKE NO REPRESENTATION THAT THE SITE OR ANY CONTENT IS FREE FROM ERRORS, VIRUSES, BUGS, OR OTHER HARMFUL COMPONENTS. FURTHER, WE MAKE NO REPRESENTATION OR WARRANTY THAT CONTENT PROVIDED ON THIS SITE IS APPLICABLE OR APPROPRIATE FOR USE IN LOCATIONS OUTSIDE OF THE UNITED STATES.
IN NO EVENT SHALL WE OR OUR AFFILIATES OR AGENTS BE LIABLE FOR ANY DIRECT, INDIRECT, PUNITIVE, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE USE OF, OR THE INABILITY TO USE, THIS SITE, WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
Under no circumstances whatsoever shall our aggregate liability resulting from or relating to your use of this Site exceed Five Dollars ($5.00).
You are solely responsible for providing, maintaining and ensuring compatibility with the Site, and all hardware, software, electrical and other physical requirements for your use of the Site.
Any and all questions, comments, suggestions, and similar materials or information that you send or submit to us on this Site, by a Post or otherwise (collectively, "Submissions"), shall become our property; and you hereby transfer, sell, and assign to us all of your right, title, and interest in and to any such Submissions, including without limitation, any and all related patent, copyright, trademark, and other intellectual property rights. We have no obligation of any kind whatsoever to maintain any confidentiality with respect to any such Submissions. We shall be free to use them for any purpose whatsoever without providing you notice or receiving your consent, and without restriction or compensation.


A fix for 3.4 and 3.5 has already been checked in. I'm creating this bug for documentation purposes only.
This problem was reported by Daniel Karlsson.
As mentioned, this is already fixed in CVS. Resolving bug.


Originally from Athens, Eva moved to London in 2010 to study and soon fell in love with the Big Smoke, meaning she stayed put after her studies were completed.
She joined our Hackney office after being approached on LinkedIn and dazzled in real life (her words, not ours!). She thrives on her ability to connect with people from any socio-economic, educational and ethnic background, and loves the fact she does a job she enjoys every single day.
Eva is not one to sit on her hands, either, fully prepared to offer suggestions and possible improvements – in the past, for example, she has suggested the deployment of a casual dress code to allow staff to be their selves and express a little bit of their personality through their choice of clothes. As Eva puts it, she enjoys being 'a quirky agent in a pool of suits'. And we wouldn't have it any other way!


text:
Marcus Iunius Brutus Caepio, vagy Quintus Caepio Brutus (Róma, i. e. 85. – Filippi, i. e. 42. október 23.) római politikus, a Julius Caesar elleni összeesküvés egyik főszervezője, a dictator egyik gyilkosa.

Életrajza
Rómában született előkelő, ám politikai szempontból nem túlzottan jelentős családban Marcus Iunius Brutus és Servilia Caepionis gyermekeként. Apai ágon őse volt az utolsó római királyt, Tarquinius Superbust elűző Lucius Iunius Brutus, édesanyja pedig az ifjabb Cato féltestvére és Julius Caesar szeretője volt. Már az ókorban rebesgették, hogy valójában Caesar volt az apja, azonban ez eléggé valószínűtlen: Brutus születésekor későbbi áldozata alig tizenöt éves volt, viszonya pedig körülbelül tíz év múlva kezdődött Serviliával. Apja proscriptiós kivégzése (Kr. e. 77) után nagybátyja, Quintus Servilius Caepio adoptálta.

Kr. e. 58-ban nagybátyjával, Catóval tartott Ciprusra annak szolgálati útján, Kr. e. 53-ban pedig Cilicia provinciában quaestorkodott. Ebben az időszakban hatalmas vagyonra tett szert uzsorakölcsönökből. Brutus kezdettől fogva a senatus ultrakonzervatívnak nevezhető republikánus optimata csoportjával szimpatizált, és a Caesar és Pompeius között kitörő polgárháborúban az utóbbi mellé állt, noha Pompeius végeztette ki apját Sulla idején. Kr. e. 49-ben csatlakozott a politikushoz a Balkánon, majd a pharszaloszi vereség után kegyelmet kért Caesartól, aki megbocsátott neki.

Caesar, aki állítólag korábban is nagyra becsülte a filozófiában és retorikában jártas, elvei mellett szilárdan kiálló Brutust – Servilia hatása sem mellékes szempont – megbocsátott Brutusnak, és Kr. e. 46-ban Gallia Cisalpina helytartójává, majd Kr. e. 44-ben praetorrá tette. Mindezzel azonban sem őt, sem jó barátját és sógorát, Caius Cassiust (aki számára Brutus járta ki a kegyelmet) nem sikerült a maga pártjára állítania. Ők ketten lettek végül a dictator meggyilkolásában végződő összeesküvés vezetői. Brutus Caesar elleni merényletben tevőlegesen is részt vett, ami a híradások szerint nagyon megrendítette a dictatort ("Et tu, mi fili, Brute?" – Te is, fiam, Brutus?  (lat.), vagy, amint Suetonius írja: "Kai su, teknon?" – Te is, fiam? (gr.)).

Március 15. után a plebs és hadsereg által "apagyilkosnak" (parricida) titulált összeesküvőknek gyorsan távozniuk kellett, noha március 17-én megegyeztek abban a caesariánusokkal, hogy tettüket nem fogják szankcionálni. Marcus Antonius consul ügyesen kihasználta a közhangulatot, és maga is sokat tett tömegek feltüzelése érdekében. Végül júliusban elvileg Kréta és Cyrene kormányzásával bízták meg őket, ám Brutus Athénba ment, Cassius pedig Syriában vette át a hatalmat. A kellemetlenkedő Caius Antoniust, Macedonia helytartóját meggyilkoltatták.

Kr. e. 43 áprilisában a mutinai háborúban elért győzelem hatására a senatus imperium maiust szavazott meg számukra, amit igyekeztek kihasználni: pénzt vertek, a keleti provinciákat hatalmas, előre beszedett adókkal sújtották, fosztogattak, sarcot szedtek be, és igyekeztek sereget gyűjteni. Végül a II. triumvirátus csapataival kellett összecsapniuk Kr. e. 42-ben, a macedoniai Philippinél. Az első ütközetben Brutus Octavianus seregével szemben győzelmet aratott, ám Cassiust legyőzte Antonius, mire öngyilkos lett. A második összecsapásra három hét múlva, október 23-án került sor, amikor a republikánus hadak végleg vereséget szenvedtek. Ekkor Brutus is öngyilkosságot követett el.

Jegyzetek

Források
 Plutarkhosz Brutus-életrajza (angol)
 Appianosz: A polgárháborúkról (angol)

Római hadvezérek, katonák
Római politikusok
Összeesküvés
I. e. 85-ben született személyek
I. e. 42-ben elhunyt személyek


We are familiar with an input and the outcome of a Business Process, some people include actions/activities into a Business Process, which I disagree with, but what is the subject? Merriam-Webster dictionary defines a term "subject" as "a person or... Read More..
In the 5th Cloud World Forum, that took place a couple days ago in London, I visited the Executive Forum sections. Corporate executives and senior management discussed different Cloud Computing related problems. Also, many came there not to share how... Read More..
I could not omit Hollis Tibbetts' BLOG "Cloud should be "top down", SaaS "bottom up"? Huh?" because it reflects on the idea of Cloud adoption top to bottom. It is not clear, however, from this BLOG or from the referred... Read More..
"Oracle CloudWorld 2013 - London" in May was a great event. It was great in organisation and the content of presentations - everyone could learn something new. For example, I listened to majority of presentations regarding security and interactions/integration between... Read More..
I have looked at "Continuous Deployment: The Dirty Details" by Mike Brittain in SideShare posted on Jan 29, 2013, and found 3 nonsense cases in this overall good presentation. 1. Presentation states, "Architecture largely does not matter" while deployments a... Read More..
Lessons from History. Manufacturing The first, a manufacturing production has formed contemporary concept of a business process. People did what the technology required and nobody objected to the process. Business Process was defined a repeatable ordered set of activities that... Read More..
I've read a brilliant white paper "As-is and To-Be Process Modelling: a Flawed and Failed Paradigm," authored by John Owens, which I highly recommend for your reading. John finally uncovers the argument that modeling a business process "as-is" does not... Read More..
According to different cloud computing experts, a cloud federation is the practice of two or more service providers interconnecting for the purpose of load balancing traffic and accommodating spikes in cloud consumer demand. Cloud federation allows one provider to wholesale... Read More..
First is first! Please, accept the warmest greetings in New 13 Year! I believe that you sacred plans will realise and you will come up with even more advanced ideas. I wish you happiness and prosperity if you need it... Read More..
Oracle Corporation offers one of the first standard-based solution that allows standards-based applications, particularly, in Java with .NET, C++ and REST clients, to be deployed and executed with no modifications (at all) on in-house platform and in Clouds. It is... Read More..


text:
Equity: China, Russia Lead DR Funding
Author: Gordon Platt
CORPORATE FINANCING NEWS
By Gordon Platt
China and Russia have returned to the global equity capital markets, following a lengthy absence. China led in the number of capital raisings using depositary receipts last year, with 14 of the 51 transactions worldwide, according to BNY Mellon. Russia led last year's ranking in terms of value of DR capital raised, thanks to TCS Group Holdings (parent of Tinkoff Credit Systems), which raised $1.1 billion in the largest issue of 2013.
TCS Group's initial public offering on the London Stock Exchange last October was the biggest IPO from a Russian company since telecom group MegaFon's $1.8 billion issue in November 2012. China's return to the DR market follows a long lull caused by accounting irregularities. Investor sentiment toward Chinese firms listing in the US has improved, and additional listings are likely, bankers say.
The broadening in the DR capital market last year, with a surge in the number of capital raisings to 51 from 31 transactions in 2012, was more significant than the decline in the total capital raised, which fell to $10.4 billion from $12.7 billion in 2012, they say. There were issues from 20 countries in 2013, up from 12 a year earlier.
COMPELLING VALUATIONS
Anthony Moro, head of emerging markets depositary receipts at BNY Mellon, says: "Emerging market valuations are becoming extremely compelling. China's economy is still growing at a 7% annual rate, and while growth in Brazil and Russia has slowed recently, this is not typical for these markets. Economic growth in emerging markets will be higher than in developed markets over the long term."
Moro says financial markets were "overly spooked" by the Federal Reserve's tapering of its bond-buying program, and that deals that were put on hold last year will eventually come to market. "I expect a continued increase in DR capital-raising issues," he says. "China is back, and it is the most active issuer."
Chinese technology companies are eager to list on US exchanges, Moro says, although most of these deals are modest in size. Companies in the Asia-Pacific region used DRs to raise more than $4.4 billion in capital last year, nearly three times the 2012 total. In addition to China, Taiwan was active for a second straight year, with six issuers raising more than $2.1 billion. Additionally, there were three issues from South Korea.
EASTERN EUROPE ACTIVE
Although Eastern European equity markets did not keep pace with the rise in Western European markets last year, they still raised nearly $2.8 billion in capital, BNY Mellon says. Russian electronic payment provider QIWI raised $212 million on Nasdaq under the JOBS Act, as well as an additional $287 million in a follow-on offering. Romania's largest natural gas supplier, Romgaz, came to market with an offshore offering and private placement of DRs that raised $185 million.
Latin America had six capital raisings involving DRs last year, totaling $1.4 billion, according to BNY Mellon. They came from companies in Colombia, Peru and Mexico.
Altogether, 258 new sponsored and unsponsored DR programs were established in 2013 from 40 countries. South African issuers established the most newly sponsored programs with 10, followed by Taiwanese companies with seven. More than 143 billion DRs valued at nearly $2.6 trillion traded last year, little changed from a year earlier. China's Baidu, Brazil's Vale and Petrobras, and the UK's Vodafone and BP were the most active in terms of value traded.
CAUTIOUS OPTIMISM
Dennis Bon, global head of depositary receipts at J.P. Morgan, says: "I am cautiously optimistic about the outlook for DR capital raising in 2014. Continued improvements in the economies of key countries provide solid underpinnings for growth in the global DR market."
New issues from a number of emerging markets companies in the second half of 2013, as well as a growing deal pipeline, indicate that there could be significant growth in IPOs this year, Bon says. "Emerging markets volatility—if it continues—will affect some markets more than others. Chinese technology-related deals will continue, but Latin America could be impacted," he says.
Although the Fed's QE tapering plans could result in higher interest rates, this would make capital raising via equity sales more attractive relative to bond deals, Bon says. "There are encouraging signs that the DR market could meaningfully improve in 2014, among them Europe's evolving economic recovery and several notable IPOs in China and Russia in the fourth quarter."
DR DEAL TOTAL RISES
Nancy Lissemore, managing director and global head of depositary receipt services at Citi, says: "If the broader markets continue to do well, DR capital raising should be strong this year. Although there was less capital raised in 2013 than a year earlier, there were more deals, and they were geographically diverse."
The Asia-Pacific region will likely be active this year, particularly China, which sprung to life at the end of last year, Lissemore says. Alibaba, China's largest e-commerce company, is planning an IPO that could value the company at $100 billion, but it remains to be seen what, if any, part of the offering will be in DR form.
There could be deals from across a broad spectrum of industries in China in 2014, with energy and TMT (technology, media and telecom) dominating, Lissemore says, adding, "We also expect to see issuers from other countries coming from financials, retail and energy."
INDUSTRY BREAKDOWN
Financials accounted for 25% of last year's DR capital raising, followed by communications with 20%, industrials with 14%, and consumer (cyclical) with 12%.
There was strong investor demand for unsponsored ADR programs in 2013, with companies from Japan and the UK the most active, Lissemore says. A total of 1,597 unsponsored DR programs are available to investors, including the 150 new programs started last year.
Several new DR programs were established last year to take advantage of the US JOBS Act, Lissemore says. The act allows emerging growth companies that qualify to submit stock-registration statements confidentially and requires limited data on executive compensation. There likely will be more DR programs coming to market this year as a result of the new law, Lissemore says.
THREE BROAD TRENDS
Edwin Reyes, global head of depositary receipts at Deutsche Bank, says: "Capital raising continued to be challenging for DR issuers last year, but there are three broad trends that may help to increase activity this year." First, companies are starting to consider Level III US listings. "This is an interesting development, as it means that there may be a reversal of the de-listing trend from US exchanges that followed the implementation of Sarbanes-Oxley in 2002," Reyes says.
Second, some eurozone nations are embarking on privatization programs that may have DR components. Privatizations are also a theme in emerging markets, where governments are looking to raise revenue, he says. Third, there are signs that DRs are being considered as an acquisition currency in M&A situations, Reyes says: "As markets rebound and M&A opportunities increase, this could become a growing trend."
Jose Sicilia, head of global equity services at Deutsche Bank, says India may lift restrictions on Level I ADRs, as well as allow capital-raising listings on foreign exchanges without a local listing. At the same time, Brazil's removal of its tax on ADR issuances is likely to boost that country's DR trading, he says.
This article appeared in issue March 2014


Stern, N. J. et al "Isolation of a Lactobacillus salivarius Strain and Purification of Its Bacteriocin, Which Is Inhibitory to Campylobacter jejuni in the Chicken Gastrointestinal System." Antimicrobial Agents and Chemotherapy 50.9 (2006): 3111-3116. Web. 19 April. 2019.


The focus of the DWA Robotics & Coding program is for students to develop high level problem solving skills through real life technological challenges. This STEM based program benefits the students in many ways as they gain familiarity with different computer systems, engage in the Scientific method, and design and build robots to achieve specific results.
From Kindergarten to Grade 6, robotics and coding are integrated into regular Science classes so every child has a great start in this important field. In junior high and high school, Robotics is a Speciality Option for students to further develop their design and programming skills.
DWA has invested in the Lego WeDo 2.0 and Mindstorms EV3 programs. The Lego base is already familiar to most students and makes building complex robots a very creative yet easy process. The focus is on ingenuity!
The students, depending on age and course, design robots using multiple functions and a variety of sensors for sound, light, colour, distance and movement to enhance their robots' capabilities. From guided builds to fully original bots, students have the opportunity to continuously explore their own ideas and abilities.
Not to be confused with the regular Physical Education class, the Sport Performance option is an additional course where students can pursue their passion for sports and athletics.
Each module features a variety of activities based on seasonal sporting opportunities depending on the semester the course is scheduled. With so many opportunities for students to stay physically active, our Sport Performance program offers students an opportunity to acquire knowledge, skills and a positive attitude that can contribute to the progression of athletic endeavours.
Active living improves a student's ability to learn, concentrate and feel good about themselves. Through participation in our program, students gain valuable life skills including leadership, communication and team working abilities that will assist their development in future years. The confidence gained from participation in activities they would otherwise not have an opportunity to experience, is instrumental in contributing to a positive educational experience for students at Delta West Academy.
We pride ourselves in developing strong community partnerships throughout the city, allowing students to become familiar with various venues in which they may pursue these activities on their own or with their family.
Media, Communication & Design (MCD) offers students the opportunity to explore and develop skills in traditional and web-based challenges on large-screen iMacs. By using industry-leading software to understand the elements and principles of design, the students are able to bring their artistic visions to life!
Creating a comprehensive digital portfolio includes digital art, photography, and live-action and animated films. Students work with trained media and design instructors to navigate new platforms to merge creativity and technology.
The students are also asked to examine different forms of media and how they impact our lives including social media. Ethically and safely navigating the online world is always a priority!
This course is an option as early as Grade 4 and gains in complexity and challenge all the way to Grade 12.
At Delta West Academy, Outdoor and Environmental Education is a complimentary course that is offered through Junior High. Using the outdoor environment as a vehicle to learn about the ecological processes and gain an awareness for living things will also allow for a greater appreciation in the relationship between human lifestyles and the environment. Students prepare for many off-campus adventures in which they can demonstrate skills and apply their knowledge to environmentally responsible outdoor activities.
Cooperation, collaboration and team building skills are also developed through this course as students learn to work together preparing for camp adventures. The bond that is created between classmates and the memories of participating in camp activities are those that will stay with a child for a life time. Building confidence and reaching beyond one's personal comfort level, lend to an overall positive and engaging education experience, which is attained at Delta West Academy.
Hands on learning programs offer students an introduction to outdoor survival skills and environmental conservation. While the leadership aspects of this course allow students to focus on personal and group development through outdoor adventure.
Through the experience, students gain a greater appreciation for who they are as individuals as well as an improved ability to interact with others.


text:
/**
 * @file Interface for performance handling. This prototype is used in stages to
 * create e.g. LOD instances.
 *
 * @author Human Interactive
 */

"use strict";

var THREE = require( "three" );

var LOD = require( "./LOD" );
var Impostor = require( "./Impostor" );

var camera = require( "../core/Camera" );
var world = require( "../core/World" );
var renderer = require( "../core/Renderer" );

/**
 * Creates the performance manager.
 *
 * @constructor
 */
function PerformanceManager() {

	Object.defineProperties( this, {
		_lods : {
			value : [],
			configurable : false,
			enumerable : false,
			writable : false
		},
		_impostors : {
			value : [],
			configurable : false,
			enumerable : false,
			writable : false
		},
		_impostorCamera : {
			value : new THREE.PerspectiveCamera(),
			configurable : false,
			enumerable : false,
			writable : false
		},
		_impostorLights : {
			value : [],
			configurable : false,
			enumerable : false,
			writable : false
		}
	} );
}

/**
 * Creates a LOD instance with direct transitions and stores it to the internal
 * array.
 *
 * @param {string} id - The id of the LOD instance.
 *
 * @returns {LOD} The new LOD instance.
 */
PerformanceManager.prototype.createDirectLOD = function( id ) {

	var lod = new LOD( id, LOD.MODE.DIRECT, camera );
	this.addLOD( lod );
	return lod;
};

/**
 * Creates a LOD instance with smooth transitions and stores it to the internal
 * array.
 *
 * @param {string} id - The id of the LOD instance.
 * @param {number} threshold - The threshold where the blending is done.
 *
 * @returns {LOD} The new LOD instance.
 */
PerformanceManager.prototype.createSmoothLOD = function( id, threshold ) {

	var lod = new LOD( id, LOD.MODE.SMOOTH, camera, threshold );
	this.addLOD( lod );
	return lod;
};

/**
 * Creates an impostor instance and stores it to the internal array.
 *
 * @param {string} id - The id of the impostor instance.
 * @param {THREE.Mesh} object - The source 3D object of the impostor.
 * @param {number} resolution - The resolution of the rendered texture.
 *
 * @returns {Impostor} The new impostor instance.
 */
PerformanceManager.prototype.createImpostor = function( id, object, resolution ) {

	var impostor = new Impostor( id, object, resolution );
	this.addImpostor( impostor );
	return impostor;
};

/**
 * Adds a single LOD instance to the internal array.
 *
 * @param {LOD} lod - The LOD instance to be added.
 */
PerformanceManager.prototype.addLOD = function( lod ) {

	this._lods.push( lod );
};

/**
 * Adds a single impostor instance to the internal array.
 *
 * @param {Impostor} impostor - The impostor instance to be added.
 */
PerformanceManager.prototype.addImpostor = function( impostor ) {

	this._impostors.push( impostor );
};

/**
 * Removes a LOD instance from the internal array.
 *
 * @param {LOD} lod - The LOD instance to be removed.
 */
PerformanceManager.prototype.removeLOD = function( lod ) {

	var index = this._lods.indexOf( lod );
	this._lods.splice( index, 1 );
};

/**
 * Removes an impostor instance from the internal array.
 *
 * @param {Impostor} impostor - The impostor instance to be removed.
 */
PerformanceManager.prototype.removeImpostor = function( impostor ) {

	var index = this._impostors.indexOf( impostor );
	this._impostors.splice( index, 1 );
};

/**
 * Removes all LOD instances from the internal array.
 */
PerformanceManager.prototype.removeLODs = function() {

	this._lods.length = 0;
};

/**
 * Removes all impostor instances from the internal array.
 */
PerformanceManager.prototype.removeImpostors = function() {

	this._impostors.length = 0;
};

/**
 * Gets a LOD instance of the internal array.
 *
 * @param {string} id - The id of the LOD instance.
 *
 * @returns {LOD} The LOD instance.
 */
PerformanceManager.prototype.getLOD = function( id ) {

	var index, lod;

	for ( index = 0; index < this._lods.length; index++ )
	{
		if ( this._lods[ index ].idLOD === id )
		{
			lod = this._lods[ index ];
			break;
		}
	}

	if ( lod === undefined )
	{
		throw "ERROR: PerformanceManager: LOD instance with ID " + id + " not existing.";
	}
	else
	{
		return lod;
	}
};

/**
 * Gets an impostor instance of the internal array.
 *
 * @param {string} id - The id of the impostor instance.
 *
 * @returns {Impostor} The impostor instance.
 */
PerformanceManager.prototype.getImpostor = function( id ) {

	var index, impostor;

	for ( index = 0; index < this._impostors.length; index++ )
	{
		if ( this._impostors[ index ].idImpostor === id )
		{
			impostor = this._impostors[ index ];
			break;
		}
	}

	if ( impostor === undefined )
	{
		throw "ERROR: PerformanceManager: Impostor instance with ID " + id + " not existing.";
	}
	else
	{
		return impostor;
	}
};

/**
 * Updates the performance manager.
 */
PerformanceManager.prototype.update = function() {

	this._updateLODs();

	this._updateImpostors();
};

/**
 * This method prepares some global data needed for all impostors (e.g. camera,
 * lights) and triggers the actual generation of all impostors.
 */
PerformanceManager.prototype.generateImpostors = function() {

	var index;

	// copy camera properties to impostor camera. we can't use the copy method
	// of the camera object, because it does automatically a deep copy. since
	// the actual camera has child objects (audio), we only want to copy
	// the most necessary data.
	this._impostorCamera.matrixWorldInverse.copy( camera.matrixWorldInverse );
	this._impostorCamera.projectionMatrix.copy( camera.projectionMatrix );

	this._impostorCamera.fov = camera.fov;
	this._impostorCamera.aspect = camera.aspect;
	this._impostorCamera.near = camera.near;
	this._impostorCamera.far = camera.far;
	this._impostorCamera.zoom = camera.zoom;

	// ensure the position of the camera is in world coordinates
	camera.getWorldPosition( this._impostorCamera.position );

	// update the internal array with the entire lighting of the actual stage
	for ( index = 0; index < world.scene.children.length; index++ )
	{
		if ( world.scene.children[ index ] instanceof THREE.Light )
		{
			this._impostorLights.push( world.scene.children[ index ] );
		}
	}

	// generate each impostor
	for ( index = 0; index < this._impostors.length; index++ )
	{
		this._impostors[ index ].generate( renderer, this._impostorCamera, this._impostorLights );
	}

	// clean up
	this._impostorLights.length = 0;
};

/**
 * Updates all LOD instances.
 */
PerformanceManager.prototype._updateLODs = function() {

	var index;

	for ( index = 0; index < this._lods.length; index++ )
	{
		this._lods[ index ].update();
	}

};

/**
 * Updates all impostor.
 */
PerformanceManager.prototype._updateImpostors = ( function() {

	var cameraWorldPosition;

	return function() {

		var index;

		if ( cameraWorldPosition === undefined )
		{
			cameraWorldPosition = new THREE.Vector3();
		}

		// the camera world position is equal for each impostor
		camera.getWorldPosition( cameraWorldPosition );

		for ( index = 0; index < this._impostors.length; index++ )
		{
			this._impostors[ index ].update( cameraWorldPosition );
		}

	};

}() );

module.exports = new PerformanceManager();

redpajama_set_name: RedPajamaGithub


text:
DISEASE & PATHOPHYSIOLOGY
IMAGING & VISUALIZATION
RETINA SURGERY
Biosimilars: Not Your Typical Generic
Although the role for this category of medicine in retina is not yet clear, cost will likely be a significant factor.
By S.K. Steven Houston III, MD
The Apple iPhone and Range Rover Evoque are well known and successful products. Wanting to claim a part of that success, other companies have come out with their own versions of each of these products. In the world of ophthalmology, the anti-VEGF drugs ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron) are also well known and successful products, and now companies are developing anti-VEGF biosimiliars in attempts to get a foothold in the anti-VEGF market, currently valued at $7.5 billion and predicted to grow over the coming decade.
This article looks at the anti-VEGF biosimilars arms race and examines what effect it may have on the ophthalmic industry and profession.
• Biosimilars are medicines that are similar to other already approved biologics and must have no significant differences in quality, effectiveness, or safety.
• Biosimilars, like the biologics they mimic, are large molecules that are developed by modified cellular processes, whereas small molecule generics are developed through chemical reactions.
• Bevacizumab (Avastin) was the original disrupter, but anti-VEGF biosimilars appear poised to make waves in this space.
BIOSIMILARS: A PRIMER
What is a biosimilar, and how does it differ from a generic drug? Biosimilars are medicines that are similar to existing, approved biologics. Biosimilars must have no significant differences in quality, effectiveness, or safety when compared with their approved reference biologic.
Calling a large-molecule biosimilar a copycat is not fair because these large-molecule agents are much more complicated to develop than small-molecule generic drugs. The generic drugs most people are familiar with are small molecules developed through chemical reactions. They are 1/1,000th the size of biosimilar molecules, which are developed by modified cellular processes. Furthermore, biosimilars such as monoclonal antibodies can degrade over time and can have significant immunogenicity. As a result, biosimilars are much more complex to design and manufacture than generic drugs.
Technically, bevacizumab (Avastin, Genentech) qualifies as a biosimilar to the approved ophthalmic anti-VEGF agent ranibizumab. However, bevacizumab is used off-label for ophthalmic indications, and it is likely destined to remain off-label despite the CATT study showing its comparative effectiveness with ranibizumab. Off-label use of bevacizumab, as shown in the 2016 American Society of Retina Specialists (ASRS)Preferences and Trends survey, approaches 75%, and it has been used by retina specialists since 2006.1 So bevacizumab may be seen as the original disrupter, but new anti-VEGF biosimilars appear poised to make waves in this space.
The Approval Process
The enactment of the Biologics Price Competition and Innovation Act in 2009 opened the door for biosimilars in health care. In 2015, filgrastim-sndz (Zarxio, Sandoz) was the first biosimilar approved by the US Food and Drug Administration.2
Following the precedent of this first approval, biosimilars from several other companies have also been approved (see sidebar The Approval Process in a Nutshell). Once the patents have expired on the reference biologic, a biosimilar can be approved as an interchangeable product for the same indications. US regulatory approval requires a head-to-head comparison of the biosimilar with the reference biologic with respect to safety, quality, and efficacy.
Biosimilars in the Retina Space
The US patents for ranibizumab and aflibercept will expire in 2020, and European patents will expire for ranibizumab in 2022 and aflibercept in 2021. Several companies are developing biosimilars for these two anti-VEGF agents.
Intas Pharmaceuticals developed Razumab as a biosimilar to ranibizumab. Razumab was approved in India in 2015. Following approval, the first three batches of drug showed an ocular inflammation rate of 10%.3,4 The issue was resolved by revising the manufacturing process. This incident highlighted the significance of biologic stability and of maintaining the quality of each batch of drug. Following this initial setback, positive experiences with Razumab were presented at the ASRS meeting in 2016, with presenters describing short-term improvement in visual acuity and reduction in central retinal thickness in treatment of neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and cystoid macular edema secondary to retinal vein occlusion.5,6 Intas Pharmaceuticals is applying to conduct phase 3 clinical studies of Razumab in the United States.
Formycon, collaborating with Santo Holding, has developed FYB201 as a biosimilar to ranibizumab and FYB203 as a biosimilar to aflibercept. A phase 3 study (NCT02611778) is enrolling patients to compare the safety, efficacy, and immunogenicity of FYB201 with those of ranibizumab. Planned enrollment is 650 patients across more than 80 centers, comparing the two agents head-to-head for treatment of wet AMD. Final data collection for the primary outcome measure is expected in March 2020.
Another company, Pfenex, collaborating with Pfizer subsidiary Hospira, has developed PF582 as a biosimilar to ranibizumab. A phase 1/2 study has been conducted, with 25 patients (13 receiving PF582, 12 receiving ranibizumab) treated with intravitreal injection each month for 3 months. Results of this small pilot study showed no meaningful differences in visual acuity, central retinal thickness, or local and systemic safety measures between the two agents. Immunogenicity was also comparable. Long-term studies with more patients are needed to demonstrate the efficacy and safety of PF582 compared with ranibizumab.
Two other companies are developing biosimilars to bevacizumab: Hetero, developing cizumab, and Reliance Life Sciences, developing bevacirel.
IS THERE A FUTURE FOR BIOSIMILARS IN RETINA?
The role of biosimilars in retina will likely be considerably less than in other fields of medicine that use biologics, mainly because of the established use of bevacizumab and the plethora of data indicating its comparable efficacy to ranibizumab and aflibercept for the treatment of patients with DME and wet AMD. In addition, the cost of bevacizumab is closer to the 80% to 90% reduction common for generic drugs, compared with the 15% to 30% reduction common for biosimilars. Because most retina surgeons already use bevacizumab as first-line therapy in many instances, and physicians have extensive experience with ranibizumab and aflibercept over several years, it will be difficult to convince these physicians to switch to a biologic that has not yet gained their trust.
However, the elephant in the room is the shifting health care landscape, with the transition from the Affordable Care Act to whatever may replace it. For insurance companies, use of a biosimilar that saves 15% to 30% of $7.5 billion will represent significant savings. We are already starting to see cost factored into future payment reimbursements from Medicare, and insurance companies are paying attention to cost of care by individual physicians. Only time will tell what role biosimilars end up playing in future retina practice. We can look forward to following these developments as we approach the year 2020.
1. American Society of Retina Specialists. Global trends in retina. www.asrs.org/international/global-trends-in-retina. Accessed April 11, 2017.
2. Chustecka Z. First biosimilar approved in US: filgrastim-sndz (Zarxio). Medscape Medical News. March 6, 2015. http://www.medscape.com/viewarticle/841021. Accessed March 29, 2017.
3. Harrison L. Modern Retina. Biosimilar for ranibiuzmab clears hurdles in India. http://modernretina.modernmedicine.com/modern-retina/news/biosimilar-ranibizumab-clears-hurdles-india. Accessed April 11, 2017.
4. Patel D. Patients report eye inflammation, Intas recalls its drug batch. The Indian Express. April 3, 2017. http://indianexpress.com/article/business/companies/undertaking-detailed-analysis-patients-report-eye-inflammation-intas-recalls-its-drug-batch-4596914/. Accessed April 11, 2017.
5. Banker A. A new biosimliar ranibizumab for retinal diseases. Paper presented at: American Society of Retina Specialists Annual Meeting; August 9-14, 2016; San Francisco, CA.
6. Joshi S. Safety and efficacy of razumab (ranibizumab) – the new biosimilar in India: our experience. Paper presented at: American Society of Retina Specialists Annual Meeting; August 9-14, 2016; San Francisco, CA.
S.K. Steven Houston III, MD
• retina surgeon at Florida Retina Institute
• financial interest: none acknowledged
• @trieyedoc; shouston3@gmail.com
Tags: Anti-VEGF
Researchers Test Stem Cell–Based Retinal Implant for Dry AMD With Encouraging Results
Physicians and researchers at the USC Roski Eye Institute have collaborated with other California institutions to show that a first-in-kind stem cell-based retinal i…
GenSight Biologics Announces Topline Results from Phase 3 Clinical Trial of GS010 in Patients with Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics announced that a phase 3 study of GS010 (rAAV2/2-ND4) in patients with Leber hereditary optic neuropathy (LHON) failed to meet its primary endpoint, with sh…
Treat-Extend-Stop Protocol for Wet AMD: Long-term Outcomes
A retrospective chart review was performed for 71 eyes of 67 patients with neovascular age-related macular degeneration (AMD) treated with intravitreal anti-vascular endotheli…
Gene Therapy Trials for Wet Age-Related Macular Degeneration
Sustained Suppression of VEGF: Looking Forward and Looking Back
Unexpected Tuberculosis Laboratory Result: The Creation of a Treatment Dilemma
Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Scott Krzywonos
skrzywonos@bmctoday.com
Janet Burk
jburk@bmctoday.com
Uveitis Resource Center
DME Resource Center
AMD Resource Center
About Retina Today
Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.
BRYN MAWR COMMUNICATIONS, LLC
Cataract & Refractive Surgery Today
Retina Today
Glaucoma Today
CollaborativeEye
MillennialEye
We use cookies to offer a better user experience and to analyze site traffic. To comply with the European General Data Protection Regulation (GDPR), we are implementing a cookie consent manager to provide residents of the EU/EEA with the ability to customize their cookies. Until this is available, your continued use of this site will be deemed as consent to use of cookies.


text:
Common App impact
Leadership and board
Jenny Rickard is President & Chief Executive Officer of Common App, a not-for-profit member organization committed to the pursuit of access, equity, and integrity in the college admission process. Each year, more than one million students, one-third of whom are first-generation, apply to college through Common App's online application. Founded in 1975, Common App serves more than 900 member colleges and universities worldwide.
Jenny has shown a strong commitment to college access as evidenced by her accomplishments as the chief enrollment officer at both the University of Puget Sound and Bryn Mawr and in admission roles at Swarthmore and New York University School of Law. Her extensive service within the national higher education community includes a wide range of roles with the College Board, Association of College Counselors in Independent Schools (ACCIS), US Department of Education, and The Common Application Board of Directors — serving as Board President from 2007 to 2008.
Within the corporate field, Jenny was a vice president responsible for higher education product strategy at PeopleSoft. She was also a consultant for the higher education software company Datatel and started her career on Wall Street at J.P. Morgan & Co.
Since Jenny joined Common App in August of 2016, the organization has developed a long-term strategic plan and roadmap and has expanded its access initiatives, including the acquisition of Reach Higher, the college access and success campaign founded by former First Lady Michelle Obama during her time in the White House, and the development of a new application system for transfer and adult students.
She currently sits on the American Council on Education's Washington Higher Education Secretariat, and is an advisory board member for Liaison GradCAS, a centralized application system for graduate admissions.
Jenny received a doctorate in higher education management from the University of Pennsylvania; a Master of Business Administration degree from New York University, Stern School of Business; and a Bachelor of Arts degree in political science from Swarthmore College.
"Common App is a proven engine for advancing college access. I believe deeply in the transformative effect that higher education has on individuals and our society. I'm committed to expanding access to such an experience and supporting my colleagues and their institutions as we all navigate the increasingly dynamic and complex enrollment landscape."
Jenny Rickard, President & CEO
Our board is made up of leaders from the college admission counseling profession and at-large experts from outside the field united by a passion for advancing college access on a global scale.
Shawn Abbott
Vice Provost for Admissions, Financial Aid, and Enrollment Management
Temple University (PA)
Vincena Allen
The SEED Foundation (DC)
Cynthia Archer
Vice Chair, Bryn Mawr College Board of Trustees
Lee Ann Backlund
Vice President for Enrollment Planning and Dean of Admission and Financial Aid
Sewanee: The University of the South (TN)
Dale Bittinger
Assistant Vice Provost of Undergraduate Admissions, Orientation, and School Partnerships
University of Maryland, Baltimore County (MD)
Clark Brigger
Executive Director of Admissions
University of Colorado, Boulder (CO)
Director, Office of Corporate Social Responsibility Executive Director, Panasonic Foundation Panasonic USA
Liz Dietz
Vice President of Student Strategy and Product Management
Jeffery Gates
Senior Vice President for Student Life and Enrollment Management
Utica College (NY)
Aliza Gilbert
Highland Park High School (IL)
Lori Greene
Vice President for Enrollment Management
Butler University (IN)
Vice President, Business Strategy and Operations
Ann Marano
College Bound Counselor
Irma Lerma Rangel Young Women's Leadership School (TX)
Logan Powell
Dean of Admission
Brown University (RI)
Karen Richardson
Princeton University (NJ)
Art Rodriguez
Vice President and Dean of Admissions and Financial Aid
Carleton College (MN)
Steve Soud
Director of College Counseling
Isidore Newman School (LA)
Jenny Rickard
Common App (Ex Officio)


text:
New Mothers' Sleep Loss Linked to Accelerated Aging
When new mothers complain that all those sleepless nights caring for their newborns are taking years off their life, they just might be right, according to the University of California Los Angeles (UCLA) researchers.
UCLA research published this study in the journal Sleep Health.
Scientists studied 33 mothers during their pregnancies and the first year of their babies' lives, analyzing the women's DNA from blood samples to determine their "biological age," which can differ from chronological age. They found that a year after giving birth, the biological age of mother who slept less than seven hours a night at the six-month mark was three to seven years older than those who logged seven hours or more. Mothers who slept less than seven hours also had shorter telomeres in their white blood cells. These small pieces of DNA at the ends of chromosomes act as protective caps, like the plastic tips on the ends of shoelaces. Shortened telomeres have been linked to a higher risk of cancers, cardiovascular and other diseases, and earlier death.
"The early months of postpartum sleep deprivation could have a lasting effect on physical health," said the study's first author, Judith Carroll, UCLA's George F. Solomon Professor of Psychobiology. "We know from a large body of research that sleeping less than seven hours a night is detrimental to health and increases the risk of age-related diseases."
While participants' nightly sleep ranged from five to nine hours, more than half were getting less than seven hours, both six months and one year after giving birth, the researchers report.
"We found that with every hour of additional sleep, the mother's biological age was younger," said Carroll, a member of the Cousins Center for Psychoneuroimmunology at UCLA's Jane and Terry Semel Institute for Neuroscience and Human Behavior. "I, and many other sleep scientists, consider sleep health to be just as vital to overall health as diet and exercise."
Carroll urged new mothers take advantage of opportunities to get a little extra sleep, like taking naps during the day when their baby is asleep, accepting offers of assistance from family and friends, and, when possible, asking their partner to help with the baby during the night or early morning. "Taking care of your sleep needs will help you and your baby in the long run," she said.
Co-author Christine Dunkel Schetter, a distinguished professor of psychology and psychiatry at UCLA, said the study results "and other findings on maternal postpartum mental health provide the impetus for better-supporting mothers of young infants so that they can get sufficient sleep -- possibly through parental leave so that both parents can bear some of the burdens of care, and through programs for families and fathers."
Dunkel Schetter added that while accelerated biological aging linked to sleep loss may increase women's health risks, it doesn't automatically cause harm to their bodies. "We don't want the message to be that mothers are permanently damaged by infant care and loss of sleep," she emphasized. "We don't know if these effects are long-lasting."
The study used the latest scientific methods of analyzing changes in DNA to assess biological aging -- also known as epigenetic aging, Dunkel Schetter said. DNA provides the code for making proteins, which carry out many functions in the cells of our body, and epigenetics focuses on whether regions of this code are "open" or "closed."
"You can think of DNA as a grocery store," Carroll said, "with lots of basic ingredients to build a meal. If there is a spill in one aisle, it may be closed, and you can't get an item from that aisle, which might prevent you from making a recipe. When access to DNA code is 'closed,' then those genes that code for specific proteins cannot be expressed and are therefore turned off."
Because specific sites within DNA are turned on or off with aging, the process acts as a sort of clock, Carroll said, allowing scientists to estimate individuals' biological age. The greater an individual's biological, or epigenetic, age, the greater their risk of disease and earlier death.
The study's cohort -- which included women who ranged in age from 23 to 45 six months after giving birth -- is not a large representative sample of women, the authors said, and more studies are needed to better understand the long-term impact of sleep loss on new mothers, what other factors might contribute to sleep loss and whether the biological aging effects are permanent or reversible.
Carroll and Dunkel Schetter reported last year that a mother's stress prior to giving birth may accelerate her child's biological aging, which is a form of "intergenerational transfer of health risk," Dunkel Schetter said.
Co-authors of the new study included researchers from the department of psychology, the department of psychiatry and biobehavioral sciences, and the department of human genetics and biostatistics at UCLA and from the psychology department at the University of Colorado at Colorado Springs.
Funding sources for the study included the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Aging, both part of the National Institutes of Health. (ANI)


text:
The Circular Space
The Scrap Space
Laptop Rescue Service
The Activity Space & The Garden Space
Adur Repair Cafe
Tickets for Advance Booking Upcoming Events
Art Club for Adults - Drawing: Next Steps
06 Jan, 14:00 – 10 Feb, 16:00
The Circular Space, Ham Rd, Shoreham-by-Sea BN43 6PA, UK
Gentle teaching of artistic techniques with Debbie. Hot drink included. This is a 6 week drawing course on either Fridays 2 to 4pm from 6 January 2023 to 10 February 2023 or Saturdays 1 to 3pm from 25 February 2023 to 1 April 2023.
Art Club for Adults - Painting: Next Steps
Gentle teaching of artistic techniques with Debbie. Hot drink included. This is a 6 week painting course on Fridays 2 to 4pm from 24 February to 31 March 2023 or Saturdays 1 to 3pm from 7 January to 11 February 2023.
Messy Makers Club
Shoreham-by-Sea, Ham Rd, Shoreham-by-Sea BN43 6PA, UK
Includes clay, glue, mud, paint and more! Wear clothes suitable for being outside and getting messy... This booking is for Mondays, 3.45 to 5.15pm from January 9th to February 6th.
Create a Story Club
Go on a story creating journey in whatever way excites you! Led by Suzie. This block is 3.45 to 4.45pm on Wednesdays 11 January to 8 February 2023.
After School Art Club: Years 4 to 7
Get arty, learn artistic techniques and about art history in a small group with Claire. This booking is for kids in years 4 to 7, Thursdays, 5.15 to 6.30pm from 12 January to 9 February 2023.
Sew a Banner!
29 Jan, 14:00 – 17:00
The Circular Space, Ham Road, Shoreham-by-Sea BN43 6PA, UK
Get your message on your clothing or a banner with the help of the Rebel Coats ladies! Learn skills in making and sewing fabric lettering.
#Bringit
03 Feb, 18:30 – 20:30
A monthly informal local poetry writers' meetup. Beginners welcome. We spend the time writing, sharing our poetry with one another and supporting one another to both write new work and find the confidence to perform at other venues.
Art Club for Adults: Mixed Media One Day Workshop
Gentle teaching of artistic techniques with Debbie. Hot drink included. Enjoy a day of creativity discovering the playful charms of making Mixed Media art. No experience required.
Valentine's Messy Makers
Messy arty, crafty fun with Lucy using lots of hearts! This session is drop off for ages 6 to 10. See also Tuesday 14th February's family session for accompanied 3 to 10 year olds.
Family Valentine's Messy Makers
Messy arty, crafty fun with Lucy using lots of hearts! You need a ticket for each child joining in. Adults come free and can have a complimentary hot drink. This session is family session for accompanied 3 to 10 year olds. See also the Monday 13th February drop off session for ages 6 to 10.
Relationship Cafe
An informal learning session to help us to think about our relationships with those around us and our communities. Each meeting is themed and will include exercises to help us think how we can connect with ourselves and others in a way that's good for them and us. This is a 'pay what you can' event.
Art Club for Adults: Introduction to Drawing One Day Workshop
05 Mar, 10:00 – 15:30
Gentle teaching of artistic techniques with Debbie. Hot drink included. Bring lunch with you.
Art Club for Adults: Introduction to Painting One Day Workshop
02 Apr, 10:00 – 15:30
© 2021 by Over the Moon Shoreham C.I.C.


text:
Pretty on the Inside
By Linda Childers
How probiotic-stocked mybody heals skin from within.
Probiotics, known as "good bacteria," have received a lot of attention for their ability to boost immunity and help with digestive problems. But a new body of research suggests that applying probiotics topically may offer anti-aging benefits.
Recognizing that the effects of probiotics might go beyond the digestive tract, entrepreneur David Watson and his wife, Christine, founded mybody, (Mybodyskincare.com) in Phoenix, Arizona.
"We decided to harness the power of topical probiotics to boost skin health and appearance," says Christine. "The mybody approach to skin care effectively treats all skin types, and decreases skin sensitivity, redness, and inflammation, while reducing fine lines and wrinkles."
Applied topically, probiotic bioactives have two specific mechanisms of action that support clinical anti-aging objectives. First, they increase the skin's ability to defend itself from environmental assault by fortifying the skin's immune system. Secondly, they stimulate cellular regeneration, increasing key structural proteins like collagen without injuring the skin or stimulating inflammatory pathways.
The Watsons are no strangers to the skin-care industry. In 1991, David developed the Biomedic line, one of the first medically dispensed skin-care lines distributed through plastic surgeons and dermatologists. He sold the company to L'Oréal in 2000 and went on to create the Philosophy line of skin-care products sold in retail stores like Sephora.
Seeking to build a skin-care line for the professional dermatology market that would combine medical grade skin care with beautiful products that women could display on their vanities, David teamed up with Christine, a former skin-care buyer at Harrods of London, to create mybody.
As a breast-cancer survivor, Christine felt it was important to create a cruelty-free skin-care line using ingredients that didn't compromise the immune system. All mybody products eschew the use of phthalates, dyes, and sulfates, and thus do not interfere with the endocrine system.
"We use ingredients the body recognizes and can process without causing inflammation," Christine says.
Indeed, the products have a calming effect on the skin, working in the same way that oral probiotics work to ease the immune system.
"We just launched two facial masks formulated with probiotics that boost the skin's immune system while providing a deep surge of hydration to thirsty skin," Christine says. Next up for mybody: A replenishing, anti-aging oil launching in 2016, rife with a unique superfood bio-oil complex made up of omega fatty acids. The upshot: vitamins and antioxidants that protect the skin from sun damage and strengthen its protective barrier, bringing out inner beauty, naturally.
beautyHealthHealthy SkinMybodyPretty on the Insideprobiotics
Winter Beauty Dos And Don'ts
DIY Beauty Treatments from Botanical Expert
Great Beauty and Health Products That Celebrities Endorse
6 Worst Foods For Your Skin


Can I have JC30M48CR card with SCP03? Can this card be set to SCP03?
Topic: How can I get the key that doesn't have alias in PKI?
Re: How can I get the key that doesn't have alias in PKI?
How can I get the key that doesn't have alias in PKI?
As the subject said,how can I get the key that doesn't have alias in PKI?
I got some java cards. However, I know nothing about these cards but the card model. Is there any method to check the failed authentication counter? And how can I know if the cards are already blocked due to too much failed tries?
Wow, a convenient method to activate JCOP tool. Thanks for sharing!
notuo wrote: Hi! If I want to send an extended length APDU, does it affect calculation of various C-MAC?
There is no effect at all. The crypto operation is the same regardless of the length of the data.
Topic: Is it feasible to adapt SCP02 for using the AES keys by some methods?
Is it feasible to adapt SCP02 for using the AES keys by some methods?
Topic: How to "logout" from my card?
How to "logout" from my card?
I have uploaded and installed an applet into javacard successfully. And I can select applet and send APDU command to my applet. But now I want to deselect the applet. I mean I want to "logout" from my card. How can I do this?


A quiet afternoon is captured. The woman reclined comfortably and engrossed in a good book takes a moment to breath in the Parisian air. She is wearing a glamorous black ball gown simply because she can. Timeless style never escapes her.